Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lipiodol Clear all
Withdrawn Phase 1 Interventional

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

NCT05490381
View directory record Official record
Conditions
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Interventions
Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
Other · Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

NCT01877187
View directory record Official record
Conditions
Liver Cancer
Interventions
Lipiodol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tebentafusp-tebn With LDT in Metastatic UM

NCT06626516
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Transarterial Chemoembolization, Proton Beam Radiotherapy
Procedure · Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 4, 2026, 8:08 AM EDT
Completed No phase listed Observational

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

NCT04459468
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lipiodol
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Chemoembolization for Lung Tumors

NCT04200417
View directory record Official record
Conditions
Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
Interventions
Chemoembolization, Mitomycin C, Lipiodol, Embospheres
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma

NCT02007954
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DEBDOX
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 4, 2026, 8:08 AM EDT
Active, not recruiting Phase 2 Interventional

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Interventions
Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Sonographic Hysterosalpingography: Oil vs Water Based Media (SHOW Trial)

NCT03604549
View directory record Official record
Conditions
Infertility
Interventions
Lipiodol UF, Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 4, 2026, 8:08 AM EDT
Terminated Phase 2 Interventional

TATE Versus TACE in Intermediate Stage HCC

NCT03145558
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Tirapazamine, Doxorubicin
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Irvine, California • Portland, Oregon • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Phase 1 Interventional

Achilles Tendinopathy Embolization

NCT07477860
View directory record Official record
Conditions
Achilles Tendinopathy (AT)
Interventions
LipioJoint
Device
Lead sponsor
Joint & Vascular Institute
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Libertyville, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

NCT06095050
View directory record Official record
Conditions
Shoulder Pain, Tendinopathy, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis, Embolization, Arterial Occlusion
Interventions
Embolization, Physical Therapy
Device · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis

NCT06859164
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Interventions
Genicular Artery Embolization, Lipiodol, Simple angiogram
Procedure · Device
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis

NCT06805942
View directory record Official record
Conditions
Plantar Fasciitis of Both Feet
Interventions
Lipiodol (ethiodized oil) injection
Device
Lead sponsor
IR Centers
Other
Eligibility
22 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 4, 2026, 8:08 AM EDT
Active, not recruiting Not applicable Interventional

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery

NCT06204159
View directory record Official record
Conditions
Hepatocellular Carcinoma, Neuroendocrine Tumors
Interventions
TACE Catheters
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

NCT00661622
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
GM-CSF, Embolization
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 4, 2026, 8:08 AM EDT
Terminated Phase 3 Interventional Results available

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

NCT02762266
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol
Radiation · Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Combination of TATE and PD-1 Inhibitor in Liver Cancer

NCT03259867
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastric Cancer
Interventions
Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
Drug · Combination Product
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Withdrawn Not applicable Interventional

Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma

NCT01489410
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Drug-Eluting Beads (DEB) with Doxorubicin, Lipiodol Ethanol Mixture
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 4, 2026, 8:08 AM EDT
Recruiting Phase 1 Interventional

Lateral Plantar Artery Embolization For Plantar Fasciitis

NCT07395128
View directory record Official record
Conditions
Plantar Fasciitis, Chronic, Plantar Fasciitis
Interventions
Lipiodol
Device
Lead sponsor
Joint & Vascular Institute
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Libertyville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 4, 2026, 8:08 AM EDT
Completed No phase listed Observational

Can Quantitative MRI After cTACE Help Predict Survival ?

NCT02173119
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
MRI post-TACE
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 4, 2026, 8:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

NCT01020812
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
Interventions
TACE, SBRT
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

NCT03259581
View directory record Official record
Conditions
Hepatocellular Carcinoma, Bilirubinemia
Interventions
Transarterial chemoembolization
Combination Product
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 4, 2026, 8:08 AM EDT
Completed Phase 2 Interventional

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

NCT02724540
View directory record Official record
Conditions
Neuroendocrine Tumor, Malignant, Liver Metastases
Interventions
Bland Embolization, Transarterial chemoembolization, Drug Eluting Beads Embolization
Device · Combination Product
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
San Francisco, California • Standford, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 4, 2026, 8:08 AM EDT